{"schema_version":"secwatch.filing_event.v1","accession":"0001778922-26-000044","form_type":"8-K","ticker":"SGP","cik":"0001778922","company_name":"SpyGlass Pharma, Inc.","filed_at":"2026-08-06T20:16:03+00:00","discovered_at":"2026-08-06T20:18:00.324379+00:00","generated_at":"2026-08-06T20:19:53.838751+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"SpyGlass Pharma Q2 net loss $19.9M; cash $234.2M; Phase 3 enrollment on track","bullets":["Net loss of $19.9M ($0.59 per share) vs $8.7M ($3.81) in Q2 2025.","Cash, cash equivalents and short-term investments of $234.2M expected to fund operations through 2028.","Enrollment in Phase 3 registrational trials of BIM-IOL System on track for completion in 2027.","BIM-DRS first-in-human trial expected to start in H2 2026.","Appointed Mike Pinder as VP Marketing; new CPT code for reimbursement pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001778922-26-000044","json":"https://secwatch.observer/filing/0001778922-26-000044.json","markdown":"https://secwatch.observer/filing/0001778922-26-000044.md","text":"https://secwatch.observer/filing/0001778922-26-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000044/0001778922-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000044/sgp-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:19:53.838751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}